DEGEVMA Biosimilar Approval: Regulatory Win, Commercial Execution Remains the Unresolved Test

FDA Approves Teva's DEGEVMA Biosimilar to Xgeva

Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA has approved DEGEVMA™ (denosumab-adet), a biosimilar to Xgeva® (denosumab). This approval covers all indications of the reference product, including the prevention of bone complications in adults with advanced cancer that has spread to the bone, treatment of giant cell tumor of bone in adults and skeletally mature adolescents, and treatment of hypercalcemia of malignancy. DEGEVMA is Teva’s second FDA-approved biosimilar in 2026, complementing PONLIMSI™ (denosumab-adet) to form a comprehensive denosumab biosimilar portfolio. This milestone aligns with Teva's "Pivot to Growth" strategy, aiming to expand access to high-quality, more affordable biologic treatment options for patients.

• DEGEVMA has received FDA approval across all indications of its reference product, Xgeva, addressing critical needs in oncology-related bone disease and hypercalcemia of malignancy. This approval is expected to significantly broaden patient access to essential biologic treatments, particularly in areas where high healthcare expenditures for biologics like denosumab are a concern, by offering a more affordable biosimilar option.
• The FDA's decision to approve DEGEVMA was supported by a comprehensive "totality of evidence," encompassing analytical and clinical data. This data rigorously demonstrated that DEGEVMA possesses a similar efficacy, safety, and immunogenicity profile to the reference product, Xgeva, ensuring no clinically meaningful differences in its performance. DEGEVMA functions as a human monoclonal antibody that inhibits RANKL, a key regulator of osteoclast activity, thereby reducing bone resorption and cancer-induced bone destruction.
• This approval marks a significant achievement for Teva, representing its second FDA-approved biosimilar in 2026. Alongside PONLIMSI (denosumab-adet), approved earlier in the year, DEGEVMA establishes Teva's comprehensive U.S. denosumab biosimilar portfolio, covering indications for both Xgeva and Prolia. This expansion is a key component of Teva's "Pivot to Growth" strategy, reinforcing its commitment to delivering high-quality, cost-effective biologic medicines and strengthening its position in complex therapeutic categories.

Addressing the Economic Burden of Bone Complications in Advanced Cancer

Skeletal-related events (SREs) — including pathologic fractures, spinal cord compression, and surgery or radiation to bone — impose a substantial financial burden on payers and healthcare systems in both the United States and Europe. In the US, bone metastases carry estimated total annual costs of $1.9 billion, with SREs affecting approximately 50% of patients with bone metastases and driving significant inpatient expenditure. Inpatient costs alone account for an estimated 49%–59% of total SRE-related costs, with mean health plan payments per hospitalization ranging from $22,390–$26,936 for pathologic fracture, $31,016–$42,094 for surgery to bone, and $43,691–$59,854 for spinal cord compression across multiple myeloma, breast cancer, and prostate cancer patient populations.

The economic impact is further amplified by comorbidities associated with disease progression. In US patients with bone metastases from solid tumors, renal impairment — a clinically relevant complication in this population — was associated with total per-patient per-year costs of $142,267, compared with $88,839 among matched controls without renal impairment (P < 0.001), a difference exceeding $50,000. Hospital costs alone accounted for $72,557 in the renal impairment group versus $27,858 in controls. In the Irish healthcare setting, the estimated average cost of care associated with adverse events in castration-resistant prostate cancer was €23,264, with approximately 40% of those costs attributed specifically to skeletal-related events — underscoring the outsized role of bone complications in driving overall disease management costs across European systems.

From a treatment cost-effectiveness standpoint, the choice of bone-protective agent carries meaningful economic implications. In the UK, zoledronic acid demonstrated a cost-effective profile versus clodronic acid in newly diagnosed multiple myeloma, with an incremental cost-effectiveness ratio of £5,443 per QALY gained and a 90% probability of cost-effectiveness at a £20,000 per QALY threshold. In the US, a lifetime Markov model evaluating denosumab versus zoledronic acid across breast cancer, prostate cancer, and other solid tumors estimated an incremental cost of $13,396 and an incremental benefit of 0.128 QALYs from a payer perspective, yielding a cost of $104,778 per QALY, while the societal perspective — incorporating direct non-medical and indirect costs — produced a more favorable estimate of $70,730 per QALY with a net monetary benefit of $10,135 in favor of denosumab.

DEGEVMA's Safety and Tolerability Profile

The knowledge base does not have sufficient information to answer this question.

DEGEVMA's Place in the Evolving Treatment Landscape

Bone-modifying agents (BMAs) are the established standard of care for preventing skeletal-related events (SREs) in adults with advanced cancer and bone metastases, with guideline recommendations spanning multiple tumor types and clinical settings. The primary agents — zoledronic acid, denosumab, and pamidronate — are differentiated by route of administration, dosing interval, renal considerations, and tumor-type-specific evidence.

• Metastatic breast cancer: Patients with evidence of bone metastases should receive BMA therapy. Guideline-endorsed options include denosumab 120 mg subcutaneously every 4 weeks; pamidronate 90 mg intravenously every 3 to 4 weeks; or zoledronic acid 4 mg intravenously every 12 weeks or every 3 to 4 weeks. Evidence is insufficient to support the use of one BMA over another in this setting. BMAs have modest analgesic effects and should not be used alone for bone pain.

• Multiple myeloma: For patients with active symptomatic disease requiring systemic therapy, with or without evidence of lytic bone destruction or compression fracture, intravenous pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended. Denosumab has shown noninferiority to zoledronic acid for SRE prevention and is an alternative, with fewer adverse events related to renal toxicity; it may be preferred in patients with renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in that setting. Bone-modifying treatment is recommended to continue for up to 2 years, with less frequent dosing considered in patients with responsive or stable disease; retreatment should be initiated at disease relapse.

• Comparative efficacy across solid tumors: A combined analysis of three pivotal phase 3 trials demonstrated that denosumab was superior to zoledronic acid in delaying time to first on-study SRE by a median of 8.21 months, reducing the risk of a first SRE by 17% (hazard ratio 0.83 [95% CI: 0.76–0.90]; P<0.001), with efficacy demonstrated for both first and multiple events and across patient subgroups. In breast and prostate cancer, denosumab showed superior SRE-prevention activity; in other solid tumors, it was noninferior to zoledronic acid.

• Safety and monitoring distinctions: Zoledronic acid requires monitoring and potential dose modification or withholding based on renal status and is associated with acute-phase reactions. Denosumab does not require renal monitoring or dose modification for renal status. Hypocalcemia is more common with denosumab. Osteonecrosis of the jaw occurs at a similar rate with both agents and is the most important shared side-effect of both compounds.

• Timing of BMA initiation: Early initiation of a BMA after bone metastasis diagnosis (defined as a waiting period of ≤6 months) showed a trend toward a longer duration of efficacy compared with delayed initiation (+5.5 vs. +3.2 months, p = 0.056), though the pooled hazard ratio demonstrated efficacy at both initiation timepoints (0.62 [0.56–0.69] vs. 0.73 [0.60–0.83]). Whether early initiation specifically prolongs time to SRE onset remains unclear.

Denosumab Biosimilar: Reshaping Bone Health Treatment Access

The recent FDA approval of DEGEVMA™, Teva's denosumab biosimilar, marks a pivotal moment for patients and the pharmaceutical market alike. Denosumab, a monoclonal antibody targeting RANKL, has established itself as a cornerstone in managing a range of serious bone-related conditions. Its efficacy in preventing skeletal complications in advanced cancer, treating giant cell tumor of bone, and addressing hypercalcemia of malignancy is well-supported by clinical evidence. For instance, studies indicate denosumab's superiority over zoledronic acid in preventing skeletal-related events in metastatic castration-resistant prostate cancer and its utility in reducing fragility fractures associated with androgen-deprivation therapy. Furthermore, it offers a crucial treatment option for severe and refractory hypercalcemia of malignancy, including in pediatric patients where other therapies may be contraindicated due to renal impairment or lack of efficacy.

This biosimilar approval is set to reshape the competitive landscape, introducing a more affordable alternative to the reference product, Xgeva®. This aligns with Teva's strategic 'Pivot to Growth,' aiming to expand access to high-quality biologic treatments. The increased availability and potential cost savings could significantly benefit healthcare systems and patients, fostering broader utilization of this important therapy. However, the introduction of a biosimilar does not diminish the need for vigilant patient management. Clinicians must remain acutely aware of denosumab's known adverse event profile, which includes:

• Hypocalcemia: Often asymptomatic but can be severe, requiring supplementation and close monitoring.

• Osteonecrosis of the Jaw (ONJ): A serious complication necessitating good oral hygiene and dental reviews.

• Atypical Fractures: Though rare, these are potential long-term risks.

While denosumab offers advantages, particularly for patients with renal insufficiency where bisphosphonates are less suitable, the long-term safety and efficacy data for bone-modifying agents beyond two years remain somewhat limited, often relying on retrospective analyses. This underscores the ongoing need for careful patient selection, comprehensive monitoring, and a nuanced understanding of the risk-benefit balance, especially as treatment durations extend. The arrival of DEGEVMA™ represents a positive step towards greater access, but it also reinforces the importance of informed clinical practice in managing complex patient populations.